Uxin

U-Xing Biotech is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative cell therapies for cancer. The company focuses on chimeric antigen receptor T-cell (CAR-T) and T-cell receptor (TCR-T) technologies to treat hematological malignancies and solid tumors. Its lead programs include UX-001, a CD19-targeted CAR-T therapy, and UX-002, which targets BCMA for multiple myeloma. U-Xing Biotech aims to improve the efficacy and safety of cell therapies through its proprietary technology platforms, including multi-target and universal CAR-T approaches. The company has established collaborations with leading medical institutions in China to advance its clinical pipeline.